All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | {| class="wikitable sortable" |- ! colspan="5" style="background-color: #CCEEEE;" | Comparison of anti-diabetic medication |- ! Drug class ! Mechanism of action ! Advantages ! Disadvantages |- | [[Sulfonylurea]]s ([[glyburide]], [[glimepiride]], [[glipizide]]) | Stimulating insulin release by pancreatic [[beta cell]]s by inhibiting the [[ATP-sensitive potassium channel|K<sub>ATP</sub> channel]] | * Inexpensive * Fast onset of action * No effect on [[blood pressure]] * No detrimental effect on [[low-density lipoprotein]] * Lower risk of [[Human gastrointestinal tract|gastrointestinal]] side effects than metformin * Convenient dosing | * Cause an average of 2–5 kg [[weight gain]] * Increase the risk of hypoglycemia * Glyburide increases risk of [[hypoglycemia]] slightly more compared to glimepiride and glipizide |
| h Japanese (ja) | {| class="wikitable sortable" |- ! colspan="5" style="background-color: #CCEEEE;" | 抗糖尿病薬の比較 |- ! ドラッグクラス ! 作用機序 ! 利点 ! 欠点 |- | [[Sulfonylurea/ja]] ([[glyburide/ja]], [[glimepiride/ja]], [[glipizide/ja]]) | [[ATP-sensitive potassium channel/ja|K<sub>ATP</sub>チャネル]]を阻害することで、膵臓[[beta cell/ja|β細胞]]からのインスリン分泌を刺激する。 | * 安価 * 作用発現が速い * [[blood pressure/ja|血圧]]には影響しない * [[low-density lipoprotein/ja|低比重リポ蛋白]]に対する有害な影響はない * メトホルミンよりも[[Human gastrointestinal tract/ja|胃腸]]副作用のリスクが低い。 * 便利な投薬 | * 平均2～5 kgの[[weight gain/ja|体重増加]]を引き起こす。 * 低血糖のリスクを高める * グリブリドはグリメピリドやグリピジドに比べて[[hypoglycemia/ja|低血糖]]のリスクをわずかに高める |